https://www.selleckchem.com/pr....oducts/DMXAA(ASA404)
5%) at 6th week (p0.0001). The patient's satisfaction was excellent 77.2% reporting to be satisfied/very satisfied with the treatment, 79.9% with inhaling and 79.0% with the handling of SMI device. 1.6% of patients reported an investigator-defined drug-related adverse event. Treatment of COPD patients with a FDC of tiotropium/olodaterol SMI for 6 weeks resulted in significant improvements in the patients' condition as assessed by patients and physicians, with no new safety findings. Treatment of COPD patients with a FDC of tio
Like
Comment
Share
